Achieve Life Sciences (ACHV) Scheduled to Post Quarterly Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) will be releasing its earnings data after the market closes on Thursday, May 9th. Analysts expect Achieve Life Sciences to post earnings of ($0.24) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings results on Thursday, March 28th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.06. On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Stock Up 3.0 %

ACHV stock opened at $4.52 on Thursday. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 4.02. The firm’s 50-day simple moving average is $4.44 and its 200 day simple moving average is $4.44. The stock has a market cap of $154.82 million, a PE ratio of -2.95 and a beta of 1.32. Achieve Life Sciences has a fifty-two week low of $3.03 and a fifty-two week high of $10.30.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ACHV shares. Oppenheimer reaffirmed an “outperform” rating and set a $18.00 price target on shares of Achieve Life Sciences in a report on Monday, April 1st. Lake Street Capital reduced their price target on Achieve Life Sciences from $19.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, March 5th. Finally, Jonestrading initiated coverage on Achieve Life Sciences in a report on Wednesday, April 17th. They set a “buy” rating and a $20.00 price target on the stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.